Journal of Arak University of Medical Sciences

Search published articles

Showing 2 results for Aghabozorgi

Comparison of Thromboemboli Prophylactic Effect of Aspirin and Low Dose Warfarin in Standard Risk Multiple Myeloma Patients that Treated with Regimens Containing Thalidomide

Seyed Amir Dadkhahi, Ali Arash Anoushirvani, Reza Aghabozorgi,
Volume 20, Issue 2 (5-2017)

Abstract

Background: Most of the current regimens in the treatment of multiple myeloma include thalidomide. Thalidomide is a modulator of the immune system and according to several studies, its main complication is thromboembolism. The aim of this study is to compare the thromboemboli prophylactic effect of aspirin and low dose warfarin in standard risk multiple myeloma patients that treated with regimens containing thalidomide.

Materials and Methods: In this double- blind clinical trial study, sixty-six patients with multiple myeloma under treatment with thalidomide-containing regimens with standard risk for thromboembolism who were admitted to Khansari hospital, entered the study according to inclusion and exclusion criteria. The incidence of thromboembolism in these patients was evaluated.

Results: Five patients in the warfarin group and 2 patients in the aspirin group had thromboemboli. Chi square analyses showed no significant difference between groups (p=0.635).

Conclusion: The results showed that both drugs are effective in preventing thromboembolism and can be used as a prophylactic treatment.

Gengenotypic Evaluation of Hsa-miR-433-3p Binding Site in the Regulatory Region of TYMS in Breast Cancer Patients

Ali Arash Anoushirvani, Azam Ahmadi, Reza Aghabozorgi, Sara Khalili, Maryam Sahraei, Taha Fereydouni, Zoha Khademi,
Volume 21, Issue 2 (5-2018)

Abstract

Abstract
Background: Breast cancer is the most common cancer in women. It has been proven the association of cause of this disease with changes in several genes. One of the pathways associated with breast cancer is the folate reuptake pathway. The key enzyme of this pathway is coded by the TYMS gene. MicroRNAs control the expression of genes by binding to their regulatory regions. In this study, we evaluated changes in the regulatory region of TYMS gene with demographic characteristics (including the grade of cancer and metastasis) in breast cancer patients.
Materials and Methods: In this study, the regulatory region of TYMS gene was investigated using related bioinformatics software. After collecting cancerous samples and DNA extraction from blood samples of normal and patients, change in the miRNA binding region by digestion with NlaIII enzyme was assayed.
Results: Bioinformatics studies showed that the restriction site of some of the endonuclease enzymes in the 3'-UTR of the TYMS gene is related to the binding region of miRNAs, including Hsa-miR-433-3p. The results indicated the correctness of the genomic purification process, the PCR and enzymatic digestion reaction. In this study, in the regulatory region, CC homozygote, AC heterozygote and AA mutant homozygote variant had differences with control group (OR: 1.3465, %95 CI: 0.7275 to 2.4923, p<0.05). Also, the association of AA genotypes with metastasis and high grade of the patients was confirmed statistically.
Conclusion: Studies have shown that some of polymorphisms in the key genes involved in cancer are directly related to their diagnosis and treatment process, and given the importance of timely diagnosis of cancer, the achievement of diagnostic biomarkers in breast cancer in the early stages will be important. Probably, the nucleotide change at the site of the microRNA binding site could be used as a diagnostic biomarker for degree of tumor progression.

Page 1 from 1

Designed & Developed by : Yektaweb